Product
SARS-CoV-2 subunit protein recombinant vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Immunogenicity and Safety of IndoVac® as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-06-22